CRIS Current Research Information System

PALLESCHI, MICHELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 147
NA - Nord America 129
AS - Asia 99
AF - Africa 25
Totale 400
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 129
SG - Singapore 86
IT - Italia 68
CI - Costa d'Avorio 23
SE - Svezia 21
DE - Germania 13
IE - Irlanda 11
FI - Finlandia 8
CH - Svizzera 5
GB - Regno Unito 5
NL - Olanda 5
CN - Cina 4
BG - Bulgaria 3
CZ - Repubblica Ceca 3
IN - India 3
JO - Giordania 3
BE - Belgio 2
HK - Hong Kong 2
RU - Federazione Russa 2
TG - Togo 2
AT - Austria 1
PH - Filippine 1
Totale 400
Salva come PNG Salva come JPEG
Città #
Singapore 79
Abidjan 23
Santa Clara 23
Bologna 17
Chandler 15
Dublin 11
Lappeenranta 8
Ashburn 7
Monzuno 7
Amsterdam 5
Bern 5
Cesena 5
Milan 4
Princeton 4
Ravenna 4
Rome 4
Amman 3
Bagnacavallo 3
Brno 3
Forlì 3
Fort Worth 3
Sofia 3
Southend 3
Boydton 2
Brussels 2
Des Moines 2
Fairfield 2
Hong Kong 2
Lomé 2
Los Angeles 2
Moscow 2
Rimini 2
Saronno 2
Senago 2
Shanghai 2
Springfield 2
Turin 2
Wilmington 2
Wustrow 2
Acton 1
Bergamo 1
Berlin 1
Cambridge 1
Florence 1
Forest City 1
Frankfurt am Main 1
Genazzano 1
Giovinazzo 1
London 1
Manila 1
Nuremberg 1
Prineville 1
San Diego 1
Shaoxing 1
Taranto 1
Vienna 1
Totale 291
Salva come PNG Salva come JPEG
Nome #
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives 67
Moving beyond parp inhibition: Current state and future perspectives in breast cancer 55
Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis 39
Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure 27
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 24
An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy 19
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study 18
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 18
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer 16
Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology 14
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial. 14
Real-world experience and clinical impact of drug-drug interactions in HR+/HER2- advanced breast cancer patients treated with abemaciclib plus endocrine therapy: the AB-ITALY study 12
Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer 11
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer 11
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab 10
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 10
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment 9
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 9
Atezolizumab plus Nab-paclitaxel in PD-L1–Positive TNBC—Letter 8
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? 8
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-Fluoroestradiol (18F-FES) CT/PET 8
Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough? 7
Eribulin in brain metastases of breast cancer: outcomes of the EBRAIM prospective observational trial 7
Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer? 7
Germline BRCA-mutated metastatic breast cancer with positive hormone receptor 6
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 6
The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer 4
ANTIANGIOGENIC AGENTS ARE INEFFECTIVE TO INCREASE COMPLETE RESPONSE RATE IN MRCC. A META-ANALYSIS 3
Ribociclib and endocrine therapy in breast cancer 3
Precision medicine: PI3K targeting in advanced breast cancer 3
Are we ready to use TMB in breast cancer clinical practice? 3
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 3
The promise of liquid biopsy in cancer: A clinical perspective 2
Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report 1
Totale 462
Salva come PNG Salva come JPEG
Categoria #
all - tutte 2.154
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.154
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202241 0 0 0 4 4 0 3 2 0 9 11 8
2022/202384 2 8 4 8 5 10 2 7 20 3 6 9
2023/2024134 1 3 0 2 1 4 6 4 67 19 17 10
2024/2025203 39 125 39 0 0 0 0 0 0 0 0 0
Totale 462